← All indications
Lymphoma, Large-Cell, Immunoblastic
Malignant lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, one or more prominent nucleoli, and abundant cytoplasm. This class may be subdivided into plasmacytoid and clear-cell types based on cytoplasmic characteristics. A third category, pleomorphous, may be analogous to some of the peripheral T-cell lymphomas (LYMPHOMA, T-CELL, PERIPHERAL) recorded in both the United States and Japan.
Drugs by status
Phase 3 trials (59)
- azacitidine
- methylprednisolone
- tioguanine
- mercaptopurine
- acalabrutinib
- aldoxorubicin
- urea
- bendamustine
- blinatumomab
- busulfan
- calaspargase pegol
- lenalidomide
- nelarabine
- polatuzumab vedotin
- prednisone
- gemcitabine
- naltrexone
- aldesleukin
- hydrocortisone
- idarubicin
- Filgrastim
- nivolumab
- inotuzumab ozogamicin
- bleomycin
- cobalamin
- hyaluronidase (human recombinant)
- leucovorin
- pegaspargase
- pixuvri
- ifosfamide
- +29 more
Phase 2 trials (155)
- ibritumomab tiuxetan
- cmv-specific t-cells
- allogeneic natural killer cells
- alx148
- atezolizumab
- sorafenib
- idecabtagene vicleucel
- venetoclax
- belinostat
- bkt-140
- brentuximab vedotin
- bryostatin
- temsirolimus
- chlorambucil
- clofarabine
- diphenhydramine
- defibrotide
- selinexor
- e7777
- etanercept
- entospletinib
- n-(4-hydroxyphenyl)all-trans retinamide
- obinutuzumab
- oblimersen sodium
- tacrolimus
- paclitaxel
- imatinib
- lapatinib
- hsc835
- beclomethasone
- +125 more
Phase 1 trials (84)
- levofloxacin
- 19-28z t cells
- fau
- dexrazoxane
- alvespimycin
- autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing cd4+/cd8+ central memory t-lymphocytes jcar014
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- azd6738
- azd9150
- irinotecan
- carfilzomib
- cilengitide
- devimistat
- dinaciclib
- valproic acid
- durvalumab
- entinostat
- ar-42
- in111 anti-cd45 monoclonal antibody bc8
- bc8
- ispinesib
- ixazomib
- methoxyamine
- morab-004
- birabresib
- carmustine
- regn3767
- ro4929097
- dalbavancin
- tanespimycin
- +54 more
Organizations
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (23)
- Seattle Genetics
- Millennium Pharmaceuticals
- Lederle
- GlaxoSmithKline
- The EMMES Corporation
- AIDS Malignancy Consortium
- Case Western Reserve University
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- University of Washington
- Northwestern University
- Rutgers University
- Stanford University
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Michigan
- University of Nebraska
- Mayo Clinic
- University of Chicago
- University of Texas at Houston
- State University of New York, Buffalo
- American Cancer Society, Inc.
Organization Involved with Phase 1 Indications (16)
- Morphotek
- Arno Therapeutics
- University of Pittsburgh
- Cancer and Leukemia Group B (CALGB)
- Johns Hopkins University
- Ohio State University
- University of Rochester
- University of Toronto
- Wake Forest University
- Wayne State University
- University of California, San Diego
- University of Colorado, Denver
- City of Hope National Medical Center
- University of Wisconsin
- Damon Runyon Cancer Research Foundation
- St. Jude Children's Hospital
Organization Involved with Other Experimental Indications (1)